Cargando…
Severe breakthrough COVID-19 after SARS-CoV-2 booster vaccination in an MS patient on ocrelizumab
Background Many patients with multiple sclerosis are treated with immunomodulating therapies. Ocrelizumab decreases humoral responses after SARS-CoV-2 vaccination. Therefore, patients are offered additional booster vaccinations to increase these responses. However, it is unknown if an additional boo...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
The Authors. Published by Elsevier B.V.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8801059/ http://dx.doi.org/10.1016/j.nerep.2022.100072 |